349 related articles for article (PubMed ID: 19383530)
1. Effect of nigrostriatal damage induced by 6-hydroxydopamine on the expression of glial cell line-derived neurotrophic factor in the striatum of the rat.
Mertens B; Massie A; Michotte Y; Sarre S
Neuroscience; 2009 Aug; 162(1):148-54. PubMed ID: 19383530
[TBL] [Abstract][Full Text] [Related]
2. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat.
Kozlowski DA; Miljan EA; Bremer EG; Harrod CG; Gerin C; Connor B; George D; Larson B; Bohn MC
Brain Res; 2004 Aug; 1016(2):170-81. PubMed ID: 15246853
[TBL] [Abstract][Full Text] [Related]
4. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
5. 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo.
Gavin AM; Walsh S; Wyatt S; O'Keeffe GW; Sullivan AM
Neurosci Lett; 2014 Feb; 561():176-81. PubMed ID: 24373993
[TBL] [Abstract][Full Text] [Related]
6. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Sharma R; McMillan CR; Tenn CC; Niles LP
Brain Res; 2006 Jan; 1068(1):230-6. PubMed ID: 16375867
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats.
Massie A; Schallier A; Mertens B; Vermoesen K; Bannai S; Sato H; Smolders I; Michotte Y
Neuroreport; 2008 Oct; 19(16):1589-92. PubMed ID: 18806690
[TBL] [Abstract][Full Text] [Related]
8. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
Yang X; Mertens B; Lehtonen E; Vercammen L; Bockstael O; Chtarto A; Levivier M; Brotchi J; Michotte Y; Baekelandt V; Sarre S; Tenenbaum L
J Gene Med; 2009 Oct; 11(10):899-912. PubMed ID: 19639608
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
Ericson C; Georgievska B; Lundberg C
Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
[TBL] [Abstract][Full Text] [Related]
10. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
Georgievska B; Carlsson T; Lacar B; Winkler C; Kirik D
Eur J Neurosci; 2004 Dec; 20(11):3121-30. PubMed ID: 15579166
[TBL] [Abstract][Full Text] [Related]
11. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
12. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
Smith AD; Kozlowski DA; Bohn MC; Zigmond MJ
Exp Neurol; 2005 Jun; 193(2):420-6. PubMed ID: 15869944
[TBL] [Abstract][Full Text] [Related]
13. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
14. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
15. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
[TBL] [Abstract][Full Text] [Related]
16. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
17. Subpopulations of striatal interneurons can be distinguished on the basis of neurotrophic factor expression.
Bizon JL; Lauterborn JC; Gall CM
J Comp Neurol; 1999 May; 408(2):283-98. PubMed ID: 10333275
[TBL] [Abstract][Full Text] [Related]
18. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
[TBL] [Abstract][Full Text] [Related]
19. Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRalpha1 and RET mRNAs in the adult rat.
Smith AD; Antion M; Zigmond MJ; Austin MC
Brain Res Mol Brain Res; 2003 Oct; 117(2):129-38. PubMed ID: 14559146
[TBL] [Abstract][Full Text] [Related]
20. Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra.
Nosheny RL; Bachis A; Aden SA; De Bernardi MA; Mocchetti I
J Neurobiol; 2006 Oct; 66(12):1311-21. PubMed ID: 16967504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
